139 related articles for article (PubMed ID: 34945856)
1. Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.
Petronilho S; Sequeira JP; Paulino S; Lopes P; Lisboa S; Chacim S; Lobo J; Teixeira M; Jerónimo C; Henrique R
J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945856
[TBL] [Abstract][Full Text] [Related]
2. EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions.
Deng Y; Chen X; Huang C; Chen G; Chen F; Lu J; Shi X; He C; Zeng Z; Qiu Y; Chen J; Lin R; Chen Y; Chen J
J Cancer; 2019; 10(9):2006-2017. PubMed ID: 31205561
[TBL] [Abstract][Full Text] [Related]
3. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
[TBL] [Abstract][Full Text] [Related]
5. [Significance of H3K27me3 and EZH2 in Predicting the Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma].
Deng YJ; Chen G; Zhu WF; Chen XH; Hong HL; Huang LM; Shi X; Chen JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):159-165. PubMed ID: 29397836
[TBL] [Abstract][Full Text] [Related]
6. A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival.
Zhang T; Zhao H; Cui Z; Xu H; Liu X; Wu Y; Li Y; Sun S; Wang P; Wang Y; Shi X
Hematology; 2020 Dec; 25(1):203-210. PubMed ID: 32476626
[No Abstract] [Full Text] [Related]
7. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
[TBL] [Abstract][Full Text] [Related]
8. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
9. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
[TBL] [Abstract][Full Text] [Related]
10. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China.
Zhou D; Li L; Bao C; Zhu J; Zhu L; Yang X; Zheng Y; Zhou M; Luo X; Xie W; Ye X
Int J Clin Exp Med; 2015; 8(12):22497-502. PubMed ID: 26885233
[TBL] [Abstract][Full Text] [Related]
11. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.
Oñate-Ocaña LF; Ponce-Martínez M; Taja-Chayeb L; Gutiérrez-Hernández O; Avilés-Salas A; Cantú-de-León D; Dueñas-González A; Candelaria-Hernández M
Rev Invest Clin; 2021 Nov; 73(6):362-370. PubMed ID: 34044429
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
13. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.
Ryan RJ; Nitta M; Borger D; Zukerberg LR; Ferry JA; Harris NL; Iafrate AJ; Bernstein BE; Sohani AR; Le LP
PLoS One; 2011; 6(12):e28585. PubMed ID: 22194861
[TBL] [Abstract][Full Text] [Related]
14. A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
Chung C
Blood Lymphat Cancer; 2022; 12():99-106. PubMed ID: 35959380
[TBL] [Abstract][Full Text] [Related]
15. How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials.
Intzes S; Symeonidou M; Zagoridis K; Pentidou A; Bezirgianidou Z; Papoutselis M; Misidou C; Roumpakis C; Spanoudaki A; Liapis K; Spanoudakis E
Ann Hematol; 2024 May; 103(5):1623-1633. PubMed ID: 38191715
[TBL] [Abstract][Full Text] [Related]
16. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
17. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
18. Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma.
Periša V; Zibar L; Knezović A; Periša I; Sinčić-Petričević J; Aurer I
Wien Klin Wochenschr; 2017 Jun; 129(11-12):411-419. PubMed ID: 27637206
[TBL] [Abstract][Full Text] [Related]
19. Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma.
Liu R; Chen Z; Wang S; Zhao G; Gu Y; Han Q; Chen B
Mol Med Rep; 2019 Oct; 20(4):3679-3690. PubMed ID: 31485671
[TBL] [Abstract][Full Text] [Related]
20. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
